Loading stock data…
Rein Therapeutics Inc (RNTX)
$1.04+0.07 (+7.08%)
Market ClosedLast close Jun 29
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rein Therapeutics Inc. in the Healthcare sector is trading at $1.04 with a market capitalization of $80M. Wall Street consensus targets $8.00 (1 analysts), implying a +669.2% move over the next 12 months. The stock is currently near its 52-week low of $0.86, remaining 18.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +669.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.23M↓ | -$3.96M↑ | -$5.49M↑ | -$6.87M↓ | -$5.61M |
| Net Income | -$5.84M↑ | -$31.97M↓ | -$5.58M↑ | -$6.82M↓ | -$5.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$79.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
150.26%
Volume
Today's trading volume
863,108
Recent News
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy
Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls
Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls